A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

NCT05394805 · clinicaltrials.gov ↗
COMPLETED
Status
156
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie